GSK plan to file up to 20 new drugs by 2020 underwhelms market

LONDON (Reuters) - GlaxoSmithKline could file up to 20 new drugs for regulatory approval before 2020 as it seeks to revitalize a portfolio hit by falling sales of best-selling inhaled lung treatment Advair, the company said on Tuesday.

Source: Reuters: Health - November 3, 2015 Category: Consumer Health News Tags: healthNews Source Type: news